BIOLOGICAL · Unmapped registry intervention
Teplizumab
Find medicine records ·
Find other trials using this name
Clinical trial
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
NCT04598893
Study summary
ClinicalTrials.govRecent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
Design: OBSERVATIONAL · Status: ACTIVE NOT RECRUITING · Phase: Not specified
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Diabetes Mellitus, Type 1unresolved
Interventions
TeplizumabBIOLOGICAL
PlaceboOTHER
Sponsors & collaborators
Provention Bio, a Sanofi Companylead sponsor
Mapped research locations
WarsawPoland2PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1ParisFrance1San DiegoCalifornia, United States1IndianapolisIndiana, United States1JacksonvilleFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04598893 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.